Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Adjuvant T-DM1 versus trastuzumab plus pertuzumab for residual disease after neoadjuvant dual HER2 blockade in HER2-positive early breast cancer: a multicenter real-world study

Despite the established benefit of adjuvant trastuzumab emtansine (T-DM1) over trastuzumab in HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant chemotherapy plus HER2-targeted therapy, comparison of efficacy between T-DM1 and dual HER2 blockade (trastuzumab plus pertuzumab, HP) remai...

Yue-Ran Jia, Shi-Hao Liang, Wei Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.